Efzofitimod Fails to Reduce Steroid Use in Pulmonary Sarcoidosis but Improves Quality of Life: Study
Written By : Medha Baranwal
Medically Reviewed By : Dr. Kamal Kant Kohli
USA: Efzofitimod was safe and well tolerated in patients with pulmonary sarcoidosis but did not significantly reduce corticosteroid doses compared with placebo at 48 weeks. However, structured steroid-tapering protocols enabled many patients to maintain substantially lower steroid doses for up to 32 weeks. Efzofitimod also improved patient-reported outcomes, including lung-related quality of life, general health, and fatigue.
Pulmonary sarcoidosis is an inflammatory disease in which immune cells form granulomas in the lungs, potentially affecting respiratory function and quality of life. Oral corticosteroids remain the standard treatment, but prolonged use can cause significant adverse effects and affect patients' overall well-being. Efzofitimod is a novel immunomodulatory fusion protein that targets the neuropilin-2 receptor and is being investigated as a potential steroid-sparing treatment.
To evaluate its efficacy and safety, Daniel A. Culver, DO, from the Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Ohio, USA, and colleagues conducted the EFZO-FIT trial, published in The Lancet Respiratory Medicine.
The phase 3 trial was conducted across 85 centres in nine countries and included adults aged 18–75 years with pulmonary sarcoidosis requiring treatment. A total of 268 participants were randomised to receive monthly intravenous efzofitimod (3 mg/kg or 5 mg/kg) or placebo for 48 weeks. All participants followed a 12-week corticosteroid tapering programme, targeting complete withdrawal.
Of the 268 participants, 264 were included in the final analysis. Their mean age was 53.8 years, and 57% were men. Average daily corticosteroid doses declined from 10.7 mg at baseline to 2.9 mg at week 48.
However, corticosteroid reduction did not differ significantly between the efzofitimod and placebo groups. The findings revealed:
- No significant steroid-sparing benefit: The placebo-adjusted change in daily corticosteroid dose was 0.02 mg in the 3 mg/kg efzofitimod group and −0.73 mg in the 5 mg/kg group, with neither difference reaching statistical significance.
- Sustained steroid reduction: Despite the absence of a significant treatment advantage, the structured tapering programme allowed many participants to maintain lower corticosteroid doses for up to 32 weeks.
- Improved patient-reported outcomes: Efzofitimod was associated with improvements in lung-related quality of life, general health and fatigue.
- Comparable serious adverse events: The proportion of patients experiencing serious treatment-emergent adverse events was similar across the three groups.
- Mostly mild adverse effects: Headache, sinusitis, wheezing, and increased aspartate aminotransferase levels were reported more frequently in the efzofitimod groups. Most adverse events were mild to moderate.
- Deaths during the trial: Two participants in the 3 mg/kg group died, one from respiratory failure and another from complications involving a pre-existing inguinal hernia. Neither death was considered related to the study treatment.
The researchers concluded that although efzofitimod demonstrated a favourable tolerability profile, it did not significantly reduce corticosteroid requirements compared with placebo at 48 weeks. However, the substantial steroid reduction achieved across treatment groups suggests that structured tapering may allow many patients with pulmonary sarcoidosis to reduce their long-term corticosteroid exposure.
Reference:
Culver, D. A., Bonella, F., Gupta, R., Spagnolo, P., Veltkamp, M., Cameli, P., Restrepo, C. I., Frye, B. C., Kameda, M., Cifrián-Martínez, J., Ali, H., Aryal, S., Carmona, E. M., Nunes, H., Obi, O. N., Hart, S. P., Sellarés, J., Azuma, A., Grutters, J. C., . . . Baughman, R. P. (2026). Efzofitimod versus placebo in patients with pulmonary sarcoidosis (EFZO-FIT): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/S2213-2600(26)00283-3
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.